AstraZeneca meets guidance as strong performance of new medicines deliver boost

Writer, Stock Market Wire
Thursday, February 14, 2019 - 07:28

AstraZeneca said Thursday a 'strong' fourth quarter led by performance of new medicines underscored its return to growth as the drugmaker met its guidance.

For the 12 months to 31 December, revenue fell 2% to $22.1bn and product sales rose 4% to $21.05bn, which was in line with guidance for low-single-digit growth. While earnings per share fell 19% to $3.46 a share, toward the upper end of guidance for earnings of $3.30 to $3.50 a share.

The in line earnings and product sales were driven by a 'strong' fourth quarter amid strong performance from new drugs, the company said.

Product sales rose 8% to $5.77bn for the quarter, from a year earlier, and core earnings were up 22% to $1.58 a share.

Growth was the led by the performance of new drugs -- especially those for cancer – as oncology sales grew 50% to $6.04bn for the year.

The company declared a second interim dividend of $1.90 per share, taking the unchanged full-year dividend per share to $2.80.

'Closing the year with another strong quarter, our performance confirmed that AstraZeneca has returned to growth,' said Pascal Soriot, Chief Executive Officer.

'Our new medicines performed particularly well across the therapy areas and the Emerging Markets business went from strength to strength'

For 2019, the company said it would target core earnings per share of $3.50 to $3.70, and full-year product sales are expected to increase in high single-digit percentage, at constant currency rates.

Core operating profit in 2019 was anticipated to increase, ahead of product sales, by a mid-teens percentage compared with a year earlier. While core operating expenses were also expected to increase by a low single-digit percentage.

Related content

Astrazeneca's lung disease treatment granted orphan drug status in US

Astrazeneca said its potential new treatment for lung disease had been granted orphan drug designation by the US Food and Drug Administration.

The company's 'potential'...

Mon, 18/03/2019 - 07:42

Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC

Goldman Sachs today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5000p (from 4080p).

Broker Forecasts data provided...

Tue, 12/03/2019 - 13:10

AstraZeneca, Merck breast cancer treatment gets EU regulatory nod

AstraZeneca and Merck said they had a received a positive opinion from EU regulators on a treatment for breast cancer.

The Committee for Medicinal Products...

Fri, 01/03/2019 - 15:11

Aston Martin and Howden Joinery

“Markets around the world take a step back amid disappointment over Donald Trump’s failure to reach a deal with North Korea and weak manufacturing data...

Thu, 28/02/2019 - 10:06

AstraZeneca heart treatment shown to be effective during trial

AstraZeneca said a trial of a treatment for heart problems showed a reduction in major adverse cardiovascular events.

The company's heart drug Themis taken together...

Mon, 25/02/2019 - 16:16